ArticleIranian journal of pathology2026
Immunohistochemical Expression of Metastasis-Associated Gene 3 (MTA3) and Epithelial-Mesenchymal Transition (EMT) Markers in Colorectal Carcinoma: A Cross-sectional Study.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Colorectal carcinoma (CRC) is a main cause of cancer-related deaths worldwide. Studying genes involved in CRC progression helps predict prognosis and develop new therapeutic modalities. Metastasis-Associated Gene 3 (MTA3) is one of these studied genes. MTA3 could regulate tumor carcinogenesis and modulate the epithelial-mesenchymal transition (EMT) pathway due to its ability to promote or suppress target gene expression. This study evaluated the immunohistochemical expression of MTA3 and EMT markers (E-cadherin and Slug) in CRC specimens. Methods: This retrospective cross-sectional study included 81 cases of primary CRC. All cases were stained with MTA3, E-cadherin, and Slug antibodies. The relations between their expression and clinicopathological parameters, as well as the relation between MTA3 and EMT markers, were assessed. Results: High MTA3 expression and preserved membranous E-cadherin were significantly related to low tumor grade, absence of lymphovascular and perineural invasion, low depth of invasion, absence of lymph node and distant metastasis, as well as early tumor stage. High Slug expression was related to higher tumor grade, high depth of invasion, presence of lymph node and distant metastasis, as well as advanced tumor stage. There was a significant correlation between high MTA3 expression and both preserved E-cadherin (rs = 0.520, P < 0.001) and low Slug expression (rs = -0.290, P = 0.009) in the studied cases. Conclusion: MTA3 is related to favorable clinicopathological parameters in CRC and could regulate EMT marker expression, suggesting that MTA3 may play a possible role in controlling tumor cell invasion and metastasis and could exhibit a potential tumor-suppressive role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.